Jan 27, 2015 · In this study, we aimed to investigate the correlation of HMGB1 expression and resistance of rectal cancer patients to chemoradiotherapy (CRT) prior to curative operation.

In these 17 studies, HMGB1 was respectively detected using immunohistochemistry (IHC) staining and qRT-PCR in cancer tissues by 11 and 2 researches, and the remaining 4 investigations evaluated the expression of serum HMGB1 using …

Sep 17, 2020 · Our results suggest that the combination of HMGB1 and CD62L dim neutrophils is a potential marker for breast cancer lung metastasis and is novel target for future prevention and therapy. Breast...

Oct 4, 2023 · To understand the role of HMGB1 in LUAD, we collected LUAD samples to perform Immunohistochemistry (IHC) and determined the expression level of HMGB1 in LUAD and adjacent nontumor tissues (Fig....

Mar 20, 2018 · However, the pathways through which cell death drives CLD progression remain elusive. Here, we tested the hypothesis that high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) with key roles in acute liver injury, may link cell death to injury responses and hepatocarcinogenesis in CLD.

Sep 26, 2023 · HMGB1 plays a crucial role in tumor growth and response to therapy and promotes both cell death and survival. HMGB1 involves different pathways associated with cancer development and progression. HMGB1 inhibition can enhance response to immune checkpoint blockade in cancer.

HMGB1 is an independent prognostic biomarker for unfavorable prognosis of patients with GBM. Released HMGB1 of GBM cells can activate AKT and ERK signaling pathways and promote GBM cells invasion in this autocrine pathway, indicating that anti-HMGB1 therapy may be a promising treatment for GBM.

Aug 8, 2014 · Background: HMGB1 is a proinflammatory cytokine produced in response to tissue injury, but its role in ALD is unknown. Results: HMGB1 increases; translocates; and undergoes acetylation, phosphorylation, and oxidation in ALD. HMGB1 ablation in hepatocytes protects against steatosis and injury in ALD. Conclusion: HMGB1 plays a key role in ALD.

Jul 31, 2023 · HMGB1 overexpression significantly promoted the malignant progression and cisplatin resistance of NSCLC in vitro and in vivo. The online version contains supplementary material available at 10.1186/s41065-023-00294-9. Keywords: High mobility group B1 (HMGB1), Non-small cell lung cancer (NSCLC), Cisplatin, Multidrug resistance (MDR)

High-mobility group box-1 (HMGB1) is a damage-associated molecular pattern (DAMP) increased in response to liver injury. Since HMGB1 is a ligand for the receptor for advanced glycation end-products (RAGE), we hypothesized that induction of HMGB1 ...